Originally published by our sister publication Specialty Pharmacy Continuum
Dozens of unscrupulous web-based sellers of glucagon-like peptide-1 agonists are evading FDA scrutiny and patient safety controls to hawk GLP-1 weight-loss medications outside of the legitimate prescription drug supply chain, according to a new research-based editorial in Annals of Pharmacotherapy.
The paper, by pharmacist researchers from the University of Connecticut School of Pharmacy in Storrs,